Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flonoltinib Maleate in Bone Marrow Proliferative Tumors
NCT05115344Phase 1Withdrawn
- Sponsor
- Guizhou Bailing Group Pharmaceutical Co., Ltd.
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of flonoltinib in Myeloproliferative Neoplasm (MPN), myelofibrosis (MF), polycythemia vera (PV) and 1 more (6 arms), sponsored by Guizhou Bailing Group Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 72 hours, Time to Maximum Plasma Concentration at 72 hours and 8 more. Planned start Nov 2021; status: withdrawn.
02
Drugs
flonoltinib
03
Conditions
Myeloproliferative Neoplasm (MPN)myelofibrosis (MF)polycythemia vera (PV)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT05115344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05115344.